8-K Announcements
6Material company update
May 21, 2026·SEC
Material company update
Mar 11, 2026·SEC
Material company update
Jan 30, 2026·SEC
VYNE Therapeutics Inc.(VYNE)Earnings, Financials & Key Ratios
VYNE•NASDAQ
Price updated Jun 19, 2026
AboutVYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.Show more
- Revenue$570K+13.8%
- EBITDA-$27M+38.7%
- Net Income-$26M+33.5%
- EPS (Diluted)-0.62+34.0%
- Gross Margin95.96%-4.0%
- EBITDA Margin-4689.82%+46.2%
- Operating Margin-5219.12%+40.1%
- Net Margin-4646.14%+41.6%
- ROE-66.33%-17.2%
VYNE Key Insights
VYNE Therapeutics Inc. (VYNE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 36.5%
- ✓Momentum leader: RS Rating 82 (top 18%)
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading at only 1.0x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Sales declining 51.4% over 5 years
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when VYNE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
VYNE Price & Volume
VYNE Therapeutics Inc. (VYNE) stock price & volume — 10-year historical chart
Loading chart...
VYNE Growth Metrics
VYNE Therapeutics Inc. (VYNE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-51.39%
3 Years6.12%
TTM-24.96%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM49.15%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM51.13%
Return on Capital
10 Years-20.51%
5 Years-66.84%
3 Years-61.34%
Last Year-74.51%
VYNE Recent Earnings
VYNE Therapeutics Inc. (VYNE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.08+55.6%
$0.18
Rev
$86,000-57.0%
$200,000
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.28-40.0%
$0.20
Rev
$130,000-25.7%
$175,000
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.17+10.5%
$0.19
Rev
$169,000+35.2%
$125,000
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.13+43.5%
$0.23
Rev
$69,000-65.5%
$200,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.08vs $0.18+55.6% | $86,000vs $200,000-57.0% |
| Q2 2026 | Mar 12, 2026 | $0.28vs $0.20-40.0% | $130,000vs $175,000-25.7% |
| Q4 2025 | Nov 6, 2025 | $0.17vs $0.19+10.5% | $169,000vs $125,000+35.2% |
| Q3 2025 | Aug 14, 2025 | $0.13vs $0.23+43.5% | $69,000vs $200,000-65.5% |
Based on last 12 quarters of dataView full earnings history →
VYNE Peer Comparison
VYNE Therapeutics Inc. (VYNE) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 DERM | 171.19M | 6.22 | -13.23 | 10.2% | -14.82% | -35.57% | 0.00 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 SKIN | 85.9M | 0.66 | -4.14 | -10.02% | -2.03% | -9.41% | 6.20 | |
 ORGO | 313.97M | 2.44 | 16.27 | 16.8% | -0.06% | -0.07% | 0.31 | |
 GDRX | 922.03M | 2.66 | 31.18 | 0.57% | 3.74% | 4.75% | 0.10 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 PCRX | 878.35M | 22.33 | 139.56 | 3.63% | 1.27% | 1.31% | 0.66 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 |
Compare VYNE vs Peers
VYNE Therapeutics Inc. (VYNE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VYNE Income Statement
VYNE Therapeutics Inc. (VYNE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 4.58M | 10.64M | 443K | 20.99M | 931K | 477K | 424K | 501K | 570K | 454K |
Revenue Growth % | 579.82% | 132.21% | -95.84% | 4638.83% | -95.57% | -48.76% | -11.11% | 18.16% | 13.77% | -24.96% |
Cost of Goods Sold | 0 | 0 | 350K | 1.39M | 0 | 0 | 0 | 0 | 23K | 6K |
COGS % of Revenue | - | - | 79.01% | 6.63% | - | - | - | - | 4.04% | - |
Gross Profit | 4.58M▲ 0% | 10.64M▲ 132.2% | 93K▼ 99.1% | 19.6M▲ 20976.3% | 931K▼ 95.3% | 477K▼ 48.8% | 424K▼ 11.1% | 501K▲ 18.2% | 547K▲ 9.2% | 448K▲ 0% |
Gross Margin % | 100% | 100% | 20.99% | 93.37% | 100% | 100% | 100% | 100% | 95.96% | 98.68% |
Gross Profit Growth % | 579.82% | 132.21% | -99.13% | 20976.34% | -95.25% | -48.76% | -11.11% | 18.16% | 9.18% | - |
Operating Expenses | 34.17M | 65.17M | 76.24M | -232.94M | 39.84M | 34.77M | 29.68M | 44.14M | 30.3M | 24.82M |
OpEx % of Revenue | 745.85% | 612.55% | 17210.38% | -1109.63% | 4279.48% | 7289.73% | 7000.47% | 8809.98% | 5315.09% | - |
Selling, General & Admin | 5.17M | 12.19M | 22.48M | 89.54M | 20.3M | 16.39M | 13.38M | 13.19M | 11.08M | 10.89M |
SG&A % of Revenue | 112.79% | 114.53% | 5074.72% | 426.54% | 2180.34% | 3435.43% | 3154.48% | 2633.13% | 1944.21% | - |
Research & Development | 29.01M | 52.99M | 53.76M | 43.53M | 19.54M | 18.39M | 16.31M | 30.95M | 19.24M | 13.93M |
R&D % of Revenue | 633.06% | 498.02% | 12135.67% | 207.37% | 2099.14% | 3854.3% | 3845.99% | 6176.85% | 3374.91% | - |
Other Operating Expenses | 0 | 0 | 0 | -366.02M | 0 | 0 | 0 | 0 | -23K | 0 |
Operating Income | -29.59M▲ 0% | -54.53M▼ 84.3% | -76.24M▼ 39.8% | 252.55M▲ 431.2% | -38.91M▼ 115.4% | -34.3M▲ 11.9% | -29.26M▲ 14.7% | -43.64M▼ 49.1% | -29.75M▲ 31.8% | -24.37M▲ 0% |
Operating Margin % | -645.85% | -512.55% | -17210.38% | 1203% | -4179.48% | -7189.73% | -6900.47% | -8709.98% | -5219.12% | -5367.62% |
Operating Income Growth % | -106.48% | -84.28% | -39.8% | 431.24% | -115.41% | 11.86% | 14.69% | -49.15% | 31.83% | - |
EBITDA | -29.59M | -54.51M | -75.89M | 252.89M | -38.8M | -34.22M | -29.26M | -43.63M | -26.73M | -24.35M |
EBITDA Margin % | -645.68% | -512.34% | -17131.38% | 1204.63% | -4167.78% | -7174.63% | -6900.47% | -8709.18% | -4689.82% | -5362.56% |
EBITDA Growth % | -106.48% | -84.26% | -39.22% | 433.22% | -115.34% | 11.8% | 14.51% | -49.13% | 38.73% | 45.22% |
D&A (Non-Cash Add-back) | 8K | 22K | 350K | 341K | 109K | 72K | 0 | 4K | 0 | 23K |
EBIT | -29.59M | -54.53M | -94.43M | -251.44M | -38.91M | -34.3M | -29.26M | -43.64M | -26.73M | -24.37M |
Net Interest Income | 517K | 3.09M | -921K | -4.39M | -5.61M | 0 | 0 | 0 | 0 | 0 |
Interest Income | 517K | 3.09M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 921K | 4.39M | 5.61M | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 517K | 3.09M | -19.11M | -508.37M | -4.85M | 363K | 1.39M | 3.83M | 3.02M | 2.65M |
Pretax Income | -29.08M▲ 0% | -51.45M▼ 76.9% | -73.7M▼ 43.3% | -255.83M▼ 247.1% | -43.76M▲ 82.9% | -33.93M▲ 22.5% | -27.87M▲ 17.9% | -39.8M▼ 42.8% | -26.73M▲ 32.8% | -21.71M▲ 0% |
Pretax Margin % | -634.57% | -483.51% | -16637.25% | -1218.63% | -4700.32% | -7113.63% | -6573.58% | -7944.71% | -4689.82% | -4782.82% |
Income Tax | -8K | 0 | -3.24M | -258K | 448K | 13K | 0 | 4K | 4K | 4K |
Effective Tax Rate % | 0.03% | 0% | 4.39% | 0.1% | -1.02% | -0.04% | 0% | -0.01% | -0.01% | -0.02% |
Net Income | -29.08M▲ 0% | -51.45M▼ 76.9% | -70.46M▼ 37.0% | -255.57M▼ 262.7% | -73.33M▲ 71.3% | -23.21M▲ 68.3% | -28.45M▼ 22.6% | -39.83M▼ 40.0% | -26.48M▲ 33.5% | -21.46M▲ 0% |
Net Margin % | -634.57% | -483.51% | -15906.09% | -1217.4% | -7876.37% | -4865.83% | -6710.38% | -7950.9% | -4646.14% | -4726.21% |
Net Income Growth % | -106.68% | -76.93% | -36.97% | -262.69% | 71.31% | 68.35% | -22.59% | -40% | 33.52% | 49.15% |
Net Income (Continuing) | -29.08M | -51.45M | -95.18M | -255.57M | -44.21M | -33.95M | -27.87M | -39.81M | -26.74M | -21.72M |
Discontinued Operations | 0 | 0 | 0 | 0 | -29.12M | 10.73M | -580K | -27K | 253K | 261K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -101.65▲ 0% | -170.94▼ 68.2% | -149.48▲ 12.6% | -141.90▲ 5.1% | -25.65▲ 81.9% | -10.65▲ 58.5% | -2.77▲ 74.0% | -0.94▲ 66.1% | -0.62▲ 34.0% | -0.50▲ 0% |
EPS Growth % | -118.65% | -68.17% | 12.55% | 5.07% | 81.92% | 58.48% | 73.99% | 66.06% | 34.04% | 51.13% |
EPS (Basic) | -101.65 | -170.94 | -149.48 | -141.90 | -25.65 | -10.65 | -2.77 | -0.94 | -0.62 | - |
Diluted Shares Outstanding | 286.04K | 300.95K | 471.39K | 1.8M | 2.86M | 3.19M | 10.27M | 42.59M | 42.77M | 42.77M |
Basic Shares Outstanding | 286.04K | 300.95K | 471.39K | 1.8M | 2.86M | 3.19M | 10.27M | 42.59M | 42.77M | 42.77M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
VYNE Balance Sheet
VYNE Therapeutics Inc. (VYNE) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 63.86M | 139.5M | 78.33M | 87.26M | 63.19M | 38.27M | 95.96M | 64.44M | 30.01M | 25.79M |
Cash & Short-Term Investments | 62.48M | 136.25M | 76.94M | 58.59M | 42.25M | 30.91M | 93.25M | 61.52M | 29.01M | 24.93M |
Cash Only | 10.21M | 49.51M | 30.78M | 57.56M | 42.25M | 30.91M | 30.62M | 19.93M | 24.03M | 24.63M |
Short-Term Investments | 49.3M | 86.74M | 46.17M | 1.03M | 0 | 0 | 62.63M | 41.59M | 4.98M | 297K |
Accounts Receivable | 786K | 0 | 0 | 15.82M | 7.58M | 5M | 0 | 0 | 0 | 0 |
Days Sales Outstanding | 62.61 | - | - | 275.04 | 2.97K | 3.83K | - | - | - | - |
Inventory | -2.98M | 0 | 0 | 7.4M | 7.29M | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | 1.94K | - | - | - | - | - | - |
Other Current Assets | 0 | 3.25M | 0 | 855K | 1.5M | 240K | 2.71M | 2.92M | 1M | 861K |
Total Non-Current Assets | 3.01M | 428K | 842K | 6.48M | 3.86M | 2.48M | 1.72M | 2.47M | 150K | 84K |
Property, Plant & Equipment | 28K | 146K | 769K | 2.14M | 354K | 0 | 207K | 206K | 90K | 84K |
Fixed Asset Turnover | 163.64x | 72.88x | 0.58x | 9.82x | 2.63x | - | 2.05x | 2.43x | 6.33x | 4.50x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 2.98M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 282K | 73K | 4.34M | 3.51M | 2.48M | 1.51M | 2.26M | 60K | 0 |
Total Assets | 66.87M▲ 0% | 139.93M▲ 109.3% | 79.17M▼ 43.4% | 93.74M▲ 18.4% | 67.05M▼ 28.5% | 40.76M▼ 39.2% | 97.69M▲ 139.7% | 66.91M▼ 31.5% | 30.16M▼ 54.9% | 25.87M▲ 0% |
Asset Turnover | 0.07x | 0.08x | 0.01x | 0.22x | 0.01x | 0.01x | 0.00x | 0.01x | 0.02x | 0.01x |
Asset Growth % | 59.01% | 109.26% | -43.42% | 18.41% | -28.48% | -39.21% | 139.67% | -31.51% | -54.92% | -210.04% |
Total Current Liabilities | 7.82M | 9.54M | 10.66M | 21.77M | 18.41M | 9.35M | 7.54M | 14.82M | 2.4M | 1.24M |
Accounts Payable | 2.46M | 3.29M | 3.77M | 4.78M | 6.51M | 2.39M | 1.66M | 2.71M | 1.04M | 261K |
Days Payables Outstanding | - | - | 3.93K | 1.25K | - | - | - | - | 16.52K | 59.51K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 1.8M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2.45M | 3.6M | 485K | 4.78M | 2.96M | 2.58M | 4.12M | 2.74M | 1.35M | 975K |
Current Ratio | 8.17x | 14.62x | 7.35x | 4.01x | 3.43x | 4.10x | 12.73x | 4.35x | 12.53x | 20.86x |
Quick Ratio | 8.55x | 14.62x | 7.35x | 3.67x | 3.04x | 4.10x | 12.73x | 4.35x | 12.53x | 20.86x |
Cash Conversion Cycle | - | - | - | 963.09 | - | - | - | - | - | - |
Total Non-Current Liabilities | 116.08M | 7K | 0 | 34.48M | 0 | 211K | 1.41M | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 33.17M | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 853K | 0 | 0 | 99K | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 109.35M | 7K | 0 | 457K | 0 | 211K | 1.31M | 0 | 0 | 0 |
Total Liabilities | 123.9M | 9.55M | 10.66M | 56.25M | 18.41M | 9.56M | 8.95M | 14.82M | 2.4M | 1.24M |
Total Debt | 0 | 0 | 700K | 34.78M | 349K | 0 | 214K | 99K | 0 | 0 |
Net Debt | -10.21M | -49.51M | -30.08M | -22.78M | -41.9M | -30.91M | -30.41M | -19.83M | -24.03M | -24.63M |
Debt / Equity | - | - | 0.01x | 0.93x | 0.01x | - | 0.00x | 0.00x | - | 0.00x |
Debt / EBITDA | - | - | - | 0.14x | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | -0.09x | - | - | - | - | - | 1.01x |
Interest Coverage | - | - | -102.53x | -57.27x | -6.94x | - | - | - | - | - |
Total Equity | -57.03M▲ 0% | 130.38M▲ 328.6% | 68.51M▼ 47.5% | 37.49M▼ 45.3% | 48.64M▲ 29.7% | 31.2M▼ 35.8% | 88.73M▲ 184.4% | 52.09M▼ 41.3% | 27.77M▼ 46.7% | 24.64M▲ 0% |
Equity Growth % | -93.72% | 328.6% | -47.45% | -45.27% | 29.72% | -35.85% | 184.39% | -41.3% | -46.69% | -188.43% |
Book Value per Share | -199.39 | 433.21 | 145.33 | 20.82 | 17.01 | 9.79 | 8.64 | 1.22 | 0.65 | 0.58 |
Total Shareholders' Equity | -57.03M | 130.38M | 68.51M | 37.49M | 48.64M | 31.2M | 88.73M | 52.09M | 27.77M | 24.64M |
Common Stock | 1K | 3K | 3K | 4K | 5K | 0 | 1K | 1K | 3K | 3K |
Retained Earnings | -59.19M | -110.64M | -184.34M | -566.2M | -639.52M | -662.74M | -691.34M | -731.17M | -757.65M | -761.24M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -51K | -96K | 24K | 0 | 0 | 0 | 26K | 20K | 2K | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VYNE Cash Flow Statement
VYNE Therapeutics Inc. (VYNE) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -28.25M | -52.73M | -65.1M | -137.08M | -56.37M | -29.2M | -25.34M | -33.97M | -33.12M | -25.74M |
Operating CF Margin % | -616.48% | -495.61% | -14695.49% | -652.99% | -6054.46% | -6121.59% | -5976.65% | -6780.84% | -5811.23% | - |
Operating CF Growth % | -1132.95% | -86.69% | -23.45% | -110.57% | 58.88% | 48.2% | 13.22% | -34.06% | 2.5% | 111.82% |
Net Income | -29.08M | -51.45M | -73.7M | -255.57M | -73.33M | -23.21M | -28.45M | -39.83M | -26.48M | -21.46M |
Depreciation & Amortization | 8K | 22K | 700K | 341K | 109K | 72K | 0 | 4K | -755K | 5K |
Stock-Based Compensation | 1.45M | 3.64M | 6.7M | 18.1M | 8.08M | 4.3M | 3.31M | 3.3M | 2.31M | 2.02M |
Deferred Taxes | 60K | 0 | 0 | 56.3M | 1.52M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 31K | -774K | -691K | 84.07M | 2.47M | -12.64M | -254K | -2.44M | 0 | -454K |
Working Capital Changes | -722K | -4.17M | 1.89M | -40.33M | 4.78M | 2.28M | 60K | 5M | -8.19M | -5.86M |
Change in Receivables | -786K | 786K | 1.36M | -17.14M | 7.71M | 11.21M | 405K | -899K | 4.21M | 5.18M |
Change in Inventory | 1.19M | 2.76M | -1.36M | -6.05M | 113K | 97K | 0 | 0 | 0 | 0 |
Change in Payables | 620K | 825K | 481K | -12.97M | -2.67M | -8.68M | -559K | 6.01M | -12.31M | -10.98M |
Cash from Investing | -15.06M | -33.88M | 41.37M | 89.11M | 1.03M | 15.67M | -57.35M | 23.36M | 37.37M | 22.24M |
Capital Expenditures | -27K | -140K | -11K | -113K | 0 | 0 | 0 | -117K | 0 | 0 |
CapEx % of Revenue | 0.59% | 1.32% | 2.48% | 0.54% | - | - | - | 23.35% | - | 0% |
Acquisitions | -25K | 0 | 40K | 38.64M | 0 | 15.67M | 5M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 25K | 0 | -40K | 38.64M | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 49.49M | 125.91M | 4.99M | 61.81M | 39.78M | 1.65M | 82.39M | -141K | -143K | -71K |
Debt Issued (Net) | 0 | 0 | 0 | 0 | -36.43M | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 50.32M | 125.42M | 4.53M | 61.64M | 75.98M | 1.68M | 82.46M | -141K | 0 | -49K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -141K | 0 | -34K |
Other Financing | -833K | 496K | 465K | 169K | 228K | -28K | -67K | 0 | -143K | -22K |
Net Change in Cash | 6.18M▲ 0% | 39.3M▲ 536.1% | -18.73M▼ 147.7% | 13.83M▲ 173.8% | -15.56M▼ 212.5% | -11.88M▲ 23.7% | -301K▲ 97.5% | -10.75M▼ 3470.8% | 4.1M▲ 138.2% | -3.58M▲ 0% |
Free Cash Flow | -28.27M▲ 0% | -52.87M▼ 87.0% | -65.11M▼ 23.1% | -137.19M▼ 110.7% | -56.37M▲ 58.9% | -29.2M▲ 48.2% | -25.34M▲ 13.2% | -34.09M▼ 34.5% | -33.12M▲ 2.8% | -25.74M▲ 0% |
FCF Margin % | -617.07% | -496.93% | -14697.97% | -653.53% | -6054.46% | -6121.59% | -5976.65% | -6804.19% | -5811.23% | -5670.48% |
FCF Growth % | -1117.66% | -87% | -23.15% | -110.71% | 58.91% | 48.2% | 13.22% | -34.52% | 2.83% | 31.48% |
FCF per Share | -98.85 | -175.68 | -138.13 | -76.18 | -19.72 | -9.17 | -2.47 | -0.80 | -0.77 | -0.60 |
FCF Conversion (FCF/Net Income) | 0.97x | 1.03x | 0.92x | 0.54x | 0.77x | 1.26x | 0.89x | 0.85x | 1.25x | 1.20x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VYNE Key Ratios
VYNE Therapeutics Inc. (VYNE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -140.29% | -70.86% | -482.2% | -170.28% | -58.14% | -47.44% | -56.57% | -66.33% | -69.57% |
Return on Invested Capital (ROIC) | - | -600.3% | -95.86% | 712.8% | -272.12% | -731.86% | -74.86% | -72.26% | -123.96% | -219.24% |
Gross Margin | 100% | 100% | 20.99% | 93.37% | 100% | 100% | 100% | 100% | 95.96% | 98.68% |
Net Margin | -634.57% | -483.51% | -15906.09% | -1217.4% | -7876.37% | -4865.83% | -6710.38% | -7950.9% | -4646.14% | -4726.21% |
Debt / Equity | - | - | 0.01x | 0.93x | 0.01x | - | 0.00x | 0.00x | - | 0.00x |
Interest Coverage | - | - | -102.53x | -57.27x | -6.94x | - | - | - | - | - |
FCF Conversion | 0.97x | 1.03x | 0.92x | 0.54x | 0.77x | 1.26x | 0.89x | 0.85x | 1.25x | 1.20x |
Revenue Growth | 579.82% | 132.21% | -95.84% | 4638.83% | -95.57% | -48.76% | -11.11% | 18.16% | 13.77% | -24.96% |
Related:VYNE Dividend History·VYNE Revenue History·VYNE Price History·VYNE P/E History·VYNE Financial Ratios·VYNE Institutional Holders
VYNE SEC Filings & Documents
VYNE Therapeutics Inc. (VYNE) SEC filings — annual & quarterly reports (10-K, 10-Q)
VYNE Frequently Asked Questions
VYNE Therapeutics Inc. (VYNE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
VYNE Therapeutics Inc. (VYNE) reported $0.5M in revenue for fiscal year 2025.
VYNE Therapeutics Inc. (VYNE) grew revenue by 13.8% over the past year. This is steady growth.
VYNE Therapeutics Inc. (VYNE) reported a net loss of $21.5M for fiscal year 2025.
Dividend & Returns
VYNE Therapeutics Inc. (VYNE) has a return on equity (ROE) of -66.3%. Negative ROE indicates the company is unprofitable.
VYNE Therapeutics Inc. (VYNE) had negative free cash flow of $25.7M in fiscal year 2025, likely due to heavy capital investments.